The US Food and Drug Administration has given Priority Review to the supplemental Biologics License Application for the use of Dupixent® as an add-on maintenance treatment for moderate-to-severe dermatitis in children aged 6 months to 5 years.
Drug Pipeline News
Latest News
Advertisement
Advertisement
Abigail Donovan, MD, discusses what brexpiprazole can do for treating schizophrenia in older children.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Top 5 pediatric health headlines you missed in May 2026
2
Pediatric clinical trials update: May 2026
3
Simple screening questions may help pediatricians identify hidradenitis suppurativa earlier
4
Jamie Wood, MD, on the significance of the Afrezza approval for pediatric diabetes
5